德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

未开盘 05-15 16:09:05

4.860

-0.190

-3.76%

最高5.300	最低4.780	成交量186.74万
今开5.300	昨收5.050	日振幅10.30%
总市值33.00亿	流通市值33.00亿	总股本6.79亿
成交额909.56万	换手率0.28%	流通股本6.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":4.86,"timestamp":1778832545008,"preClose":5.05,"halted":0,"volume":1867409,"delay":0,"changeRate":-0.037623762376237525,"floatShares":679000000,"shares":679000000,"eps":-0.43677086922474545,"marketStatus":"未开盘","change":-0.19,"latestTime":"05-15 16:09:05","open":5.3,"high":5.3,"low":4.78,"amount":9095555,"amplitude":0.10297,"askPrice":4.87,"askSize":4500,"bidPrice":4.86,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.44826483946750195,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":0,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":5.05,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":1.1651434729016341,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00909","09858","02285","09626","06660","02096","02256","01833","01783","06186","02618","06060","01952","01548","06963","09992","81024","02252","06160","06049","01060","02171","02126","03692","02276","02172","06609","09888","02192","00719","01357","09688","00762","00013","00136","01951","02197","02306","09699","00169","06969","01024","03700","06996","02013","02158","03888","01440","00772","01905"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188860039","title":"德琪医药-B 4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188860039","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188860039?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:36","pubTimestamp":1778150199,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年5月7日发布2026年4月30日止月份的证券变动月报表。报告显示，公司期内注册股本维持2,000,000,000股，面值每股0.0001美元，注册股本总额仍为200,000美元。已发行股份为679,244,132股，库存股份202,500股，合计679,446,632股，与上月底相同。同时，公司确认符合香港联交所上市规则所规定的公众持股量要求。截至4月末，公司股本结构保持稳定，未见其他股份发行及回购活动。德琪医药-B表示已遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112683220","title":"德琪医药-B2025年收入同比增14.5%至1.05亿元 研发投入下降助推亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1112683220","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112683220?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:21","pubTimestamp":1777454477,"startTime":"0","endTime":"0","summary":"德琪医药-B在截至2025年12月31日止年度中，收入自2024年的人民币0.92亿元增至1.05亿元，同比增长14.5%。年内亏损则由2024年的人民币3.193亿元下降至2.391亿元，经调整后亏损由3.04亿元缩减至2.015亿元，降幅达33.7%，主要系研发等成本的管控效果所致。公司在研发费用方面从2024年的人民币2.589亿元降至1.691亿元；销售及分销开支由7,370万元减少至6,916.2万元；行政开支由1.063亿元降至8,747万元，使整体费用水平下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B2025年收入同比增14.5%至1.05亿元 研发投入下降助推亏损大幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138551243","title":"德琪医药-B拟回购不超过已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138551243","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138551243?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:18","pubTimestamp":1777454300,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年4月29日发布公告，计划在即将召开的股东周年大会上寻求一般性授权，拟于香港联交所回购不超过已发行股份总数的10%。以最后实际可行日期679,244,132股已发行股份为基准，最高可回购的股份数量约为67,924,413股。根据有关安排，如回购议案获得通过，公司将有权在未来适当时机于香港联交所执行购回操作。为办理大会相关事宜，公司在2026年6月5日至6月10日期间暂停登记过户。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B拟回购不超过已发行股本10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173334840","title":"德琪医药-B更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173334840","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173334840?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:25","pubTimestamp":1775730357,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年4月9日发布2026年3月的股份变动月报表。公告显示，截至3月31日，公司注册股本保持在2,000,000,000股，面值为每股USD 0.0001，总额USD 200,000。本月未出现注册股本增减变动。截至3月31日，公司已发行股份为679,244,132股，库存股份为202,500股，合计679,446,632股，较上月底无变化。本月内未发生新增发行、购回或注销活动，股本总数维持稳定。2022年受限制股份单位计划当月亦有178,000股限制性股票单位失效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625302749","title":"德琪医药-B(06996)授出合共190万份购股权及25万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625302749","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625302749?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:13","pubTimestamp":1775564039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，于2026年4月2日，本公司根据2020年股权激励计划向五名承授人授出合共190万份购股权，并根据2022年受限制股份单位计划向其中四名承授人授出25万份受限制股份单位，惟须待承授人接纳并遵守上市规则以及2020年股权激励计划及2022年受限制股份单位计划的各自条款后，方可作实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178298832","title":"异动解读 | 德琪医药-B盘中大涨5.81%，执行董事增持及与优时比授权协议提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1178298832","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178298832?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:16","pubTimestamp":1774491406,"startTime":"0","endTime":"0","summary":"德琪医药-B今日盘中股价大幅上涨5.81%，引起了市场的广泛关注。根据协议，德琪医药将获得8000万美元的首付款及近期里程碑付款，并有资格在未来获得最高约11亿美元的里程碑付款以及基于净销售额的分级特许权使用费。此外，分析报告指出，德琪医药作为一家专注于创新抗肿瘤药物的生物制药公司，其2025年度收入同比增长14.5%至1.05亿元人民币，亏损也显著收窄。内部增持与重大利好的授权协议共同作用，提振了市场对公司价值的认可和股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622020093","title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020093","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622020093?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:14","pubTimestamp":1774437259,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，3月24日，执行董事龙振国增持德琪医药(06996)23.5万股，每股作价4.136港元，总金额约为97.2万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","06996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804144","title":"【券商聚焦】交银国际维持德琪医药(06996)买入评级  指其2026年有望盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804144","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622804144?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:13","pubTimestamp":1774415596,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，德琪医药 2025年收入同比+15%至1.05亿元，亏损收窄至2.39亿元。展望2026年，与优时比达成的ATG-201交易有望贡献8,000万美元近期付款，公司预计将显著增厚业绩并实现盈亏平衡，研发投入将有所回升。综合考虑2025全年业绩和ATG-201交易对未来业绩的增厚作用，该机构上调公司2026-27年收入及盈利预测，上调DCF目标价至10港元。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977194","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169378976","title":"异动解读 | 德琪医药-B盘中大涨5.23%，业绩改善及管理层增持提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1169378976","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169378976?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:50","pubTimestamp":1774403456,"startTime":"0","endTime":"0","summary":"德琪医药-B今日盘中大涨5.23%，引起了市场的广泛关注。消息面上，公司近期公布了2025年年度业绩，显示营收同比增长14.56%至1.05亿元，经调整后年内亏损同比收窄33.7%至2.02亿元，同时公司现金储备充足，核心临床管线取得积极进展，管理层预计今年会陆续达成更多合作。此外，公司创始人、首席执行官兼董事长梅建明博士，执行董事兼首席财务官龙振国先生，以及企业副总裁兼董事会秘书曹洋先生于近期在公开市场合计增持了公司股份，总代价约为385.3万港元。此举被市场解读为管理层对公司长期投资价值及未来发展前景抱有坚定信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622126670","title":"德琪医药-B(06996)获创始人、首席执行官、董事长及其他管理层增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622126670","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622126670?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:19","pubTimestamp":1774397993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，本公司董事会获本公司创始人、执行董事、首席执行官兼董事长梅建明博士告知，于2026年3月23日及24日，梅博士透过其控制的一间实体于公开市场以平均价格每股约0.512美元购入本公司合共20万股普通股，占已发行股份总数约0.029%。在遵守适用法律及监管规定的前提下，彼等不排除于适当时候进一步增持本公司股份的可能性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622509942","title":"直击业绩会 | 德琪医药2025年亏损收窄，管理层称预计今年会陆续达成更多合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622509942","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622509942?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:49","pubTimestamp":1774367382,"startTime":"0","endTime":"0","summary":"3月20日，德琪医药（6996.HK）发布2025年年度业绩公告，并于3月23日召开业绩说明会，披露了全年经营数据及核心管线、技术平台的最新进展。财务数据显示，德琪医药2025年实现营业收入1.05亿元，同比增长14.56%，经调整后年内亏损（扣除汇兑差异净额）为2.02亿元，上年同期亏损为3.04亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682959074.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682959074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","BK1583","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165244984","title":"异动解读 | 德琪医药-B盘中大涨7.65%，2025年度业绩亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1165244984","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165244984?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:38","pubTimestamp":1774319924,"startTime":"0","endTime":"0","summary":"德琪医药-B（06996）今日盘中大涨7.65%，引起了市场的广泛关注。消息面上，公司发布了截至2025年12月31日止的年度业绩。报告显示，集团收入达到人民币1.05亿元，同比增长14.56%；研发开支为1.69亿元，同比减少34.69%；年内亏损为2.39亿元，同比减少25.10%；经调整年内亏损为2.33亿元，同比收窄23.50%。公告指出，收入增长主要得益于中国内地市场贡献加速，市场渗透率稳步提升以及商业化合作不断深化。这些积极的财务数据，尤其是亏损的大幅收窄，增强了投资者对公司未来盈利能力的信心，从而推动了股价的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621034622","title":"港股异动 | 德琪医药-B(06996)盘中涨超3% 2025年度经调整年内亏损同比收窄23.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034622","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621034622?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:33","pubTimestamp":1774319622,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B(06996)盘中涨超3%，截至发稿，涨3.57%，报4.06港元，成交额679.49万港元。消息面上，近日，德琪医药-B发布截至2025年12月31日止年度业绩，该集团取得收入人民币1.05亿元(单位下同)，同比增加14.56%；研发开支1.69亿元，同比减少34.69%；年内亏损2.39亿元，同比减少25.10%；经调整年内亏损2.33亿元，同比减少23.50%；每股亏损0.38元。公告称，收入增加主要是由于中国内地贡献加速所致，得益于市场渗透率稳步提升及商业化合作不断深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","06996","BK4585","BK1191","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786754","title":"德琪医药-B(06996)发布年度业绩 经调整年内亏损2.33亿元 同比减少23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786754","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786754?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:35","pubTimestamp":1773995726,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布截至2025年12月31日止年度业绩，该集团取得收入人民币1.05亿元(单位下同)，同比增加14.56%;研发开支1.69亿元，同比减少34.69%;年内亏损2.39亿元，同比减少25.10%;经调整年内亏损2.33亿元，同比减少23.50%;每股亏损0.38元。公告称，收入增加主要是由于中国内地贡献加速所致，得益于市场渗透率稳步提升及商业化合作不断深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618935416","title":"每日卖空追踪 | 德琪医药-B 03月10日卖空量成交26.75万股，卖空比例为1.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618935416?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131438,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月10日，涨11.5%，卖空量成交26.75万股，较上一交易日减少48.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618497935","title":"德琪医药-B盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618497935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618497935?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:41","pubTimestamp":1773106901,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时41分，德琪医药-B股票出现异动，股价快速上涨5.00%。截至发稿，该股报4.200港元/股，成交量55.05万股，换手率0.08%，振幅4.50%。资金方面，该股资金流入115.616万港元，流出105.306万港元。德琪医药-B股票所在的药品行业中，整体涨幅为0.65%。德琪医药-B公司简介：德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要在亚太地区开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618260871","title":"德琪医药-B(06996.HK)拟3月20日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618260871","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618260871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:07","pubTimestamp":1773097622,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨德琪医药-B(06996.HK)宣布，本公司将于2026年3月20日(星期五)举行董事会会议，藉以(其中包括)考虑并批准本公司及其附属公司截至2025年12月31日止年度业绩及其发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32055270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","06996","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628681","title":"China International Capital Corporation Limited增持德琪医药(06996)62.7万股 每股作价约3.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628681","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618628681?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:53","pubTimestamp":1773053581,"startTime":"0","endTime":"0","summary":"据香港联交所最新数据显示，3月4日，China International Capital Corporation Limited增持德琪医药(06996)62.7万股，每股作价3.0616港元，总金额约为191.96万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","06996","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618117935","title":"近期交易合作|正大天晴小分子靶向药授权赛诺菲，德琪医药双抗授权优时比","url":"https://stock-news.laohu8.com/highlight/detail?id=2618117935","media":"药菓","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618117935?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:00","pubTimestamp":1773050411,"startTime":"0","endTime":"0","summary":"2026近期合作 & 交易事件01 睿跃生物被Gyre收购02 黑石押注梯瓦开发TL1A单抗03 正大天晴新药授权赛诺菲04 德琪医药CD3/CD19双抗授权给优时比05 施维雅25亿美元收购Day One01睿跃生物被Gyre收购2026年3月2日，美国Gyre Therapeutics宣布将以全股票交易方式收购睿跃生物，交易估值约3亿美元。03正大天晴新药授权赛诺菲3月4日，中国生物制药子公司正大天晴已与赛诺菲就JAK/ROCK抑制剂罗伐昔替尼在全球的开发、生产及商业化订立独家授权协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.2098},{"period":"3month","weight":0.4006},{"period":"6month","weight":-0.0021},{"period":"1year","weight":0.5},{"period":"ytd","weight":0.2823}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.028348},{"month":6,"riseRate":0.2,"avgChangeRate":-0.111296},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000904},{"month":8,"riseRate":0.4,"avgChangeRate":-0.030428},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}